^(99m)Tc-MIBI显像预测乳腺癌新辅助化疗疗效的临床应用

Clinical application of ^(99m)Tc-MIBI imaging for the prediction of breast cancer response to neoadjuvant chemotherapy

目的探讨99mTc-MIBI显像预测乳腺癌新辅助化疗(NCT)疗效的临床价值。方法 50例局部进展期乳腺癌(LABC)患者化疗前行99m Tc-MIBI显像,计算早期摄取比值(EUR)、晚期摄取比值(DUR)及清除率[WR=(EURDUR)/EUR×100%]。按照WHO制定的实体瘤疗效评定标准评价疗效,对化疗有效组及化疗无效组WR、EUR、DUR进行统计学比较。结果化疗有效组与化疗无效组在WR、EUR、DUR值比较差异均有统计学意义(P<0.05)。结论99mTc-MIBI乳腺肿瘤显像中摄取与清除率WR在治疗有效组与无效组中均有统计学意义,肿瘤99mTc-MIBI摄取越高,清除率越低,疗效越好,可有效预测LABC患者术前NCT疗效。

Objective To discuss the clinical value of ^99mTc - MIBI imaging for the prediction of breast cancer to neoadjuvant chemotherapy （NCT）. Methods Fifty cases of locally advanced breast cancer （LABC） patients underwent ^99mTc - MIBI imaging, and the computational early uptake ratio （EUR）, delayed uptake ratio （DUR） and washout rate （ WR, % ） [ WR = （ EUR - DUR）/EUR x 100% ] were calculated. Clincial response was based on WHO criteria. WR, EUR, DUR of the effective chemotherapy group and ineffective chemotherapy group were statistically compared. Results WR , EUR and DUR were statistically significantly different （P 〈 0. 05 ） between effective chemotherapy group and ineffective chemotherapy group. Conclusion ^99mTc -MIBI breast tumor imaging uptake and washout rate in the treatment of effective group and ineffective groups have significant difference, the higher the tumor ^99mTc - MIBI uptake, washout rate is lower, the better the effect is, ^99mTc - MIBI breast tumor imaging can effectively predict the efficacy of NCT of LABC patients before operation.